Delving into the Latest Updates on Anti-CD1a CAR-T cells(The Affiliated Hospital of Xuzhou Medical University) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms-

Target

CD1A

Action

inhibitors

Mechanism

CD1A inhibitors(CD1a molecule inhibitors), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Refractory T Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic Leukemia/Lymphoma

Inactive Indication-

Originator Organization

Affiliated Hospital of Xuzhou Medical University

Active Organization

Affiliated Hospital of Xuzhou Medical University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

In this issue of Blood, a novel approach to the treatment of T-acute lymphoblastic leukemia (T-ALL) using chimeric antigen receptor (CAR) T cells redirected against CD1a1 in in vitro and xenograft models.CD1a is a transmembrane glycoprotein that presents self or bacterial derived lipids to specialized T cells.Importantly, when anti-CD1a CAR T cells were incubated with fetal thymocytes, the majority of cells were preserved, indicating this therapy might not induce thymic ablation.CAR T-cell therapy for T-ALL and offers hope that the considerable success of CAR T cells in B-ALL can soon be extended to patients with T-ALL.

100 Deals associated with Anti-CD1a CAR-T cells(The Affiliated Hospital of Xuzhou Medical University)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory T Acute Lymphoblastic Leukemia	Phase 2	China	Affiliated Hospital of Xuzhou Medical University	01 Feb 2023
T-cell Acute Lymphoblastic Leukemia/Lymphoma	Phase 2	China	Affiliated Hospital of Xuzhou Medical University	01 Feb 2023